A Europe-based private equity firm founded in 2009 has a fund focused solely on oncology. The firm aims to fill the gap between equity and acquisition, and would be the first to get involved in assets that are seeking to spin-out of universities or research institutes. The firm typically acquires stakes and identifies ways to aggregate oncology technologies. The firm’s investment size ranges from $10M-$25M dependent on the company and product. The firm typically seeks co-investors to participate in a round. The firm has predominantly invested in companies based in the UK, though is open to investments on a global level, and is particularly seeking new opportunities in the US.
The firm invests in all sectors and subsectors of technology in oncology – therapeutics, 510K and PMA medical devices, diagnostics, and healthcare IT, along with oncology technology in palliative care. The firm is particularly loyal to its portfolio companies, as it typically makes investments in early-stage post proof-of-concept companies, and remains in the investment until commercialization.
The firm will help fill the management team, and may actively manage; takeover the management; participate in the advisory board; and/or advise the company after an investment.
If you are interested in more information about this investor and other investors tracked by LSN, please email firstname.lastname@example.org.